Neil Osterweil BOSTON — Patients with metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) without cirrhosis who took daily low-dose aspirin in a double-blind randomized trial demonstated significant reductions in liver fat content over 6 months compared with similar patients who took a placebo, study results show. “In MASLD without cirrhosis, low-dose aspirin, 81 milligrams daily,...